InSure® ONE: Why Quest Diagnostics?

Quest Diagnostics is the world's leading cancer diagnostics company. We are the first commercial laboratory in the U.S. to offer a laboratory-developed test, InSure® ONE, based on the Septin9 biomarker as an aid to colon cancer detection.InSure® ONE; is a convenient blood test that aids in the detection of colorectal cancer in patients non-adherent to current testing approaches.

In addition, we offer InSure® fecal immunochemical test (FIT), an FDA-cleared fecal occult blood test (FOBT) for use in screening for sources of lower gastrointestinal bleeding, based on laboratory testing of a stool-based specimen.

Quest Diagnostics also offers mutation testing to help predict if a patient with metastatic colorectal cancer will respond to certain therapies and genetic testing to aid in evaluating a patient's inherited predisposition to colorectal cancer.In addition, the company provides anatomic pathology testing services for colorectal cancer, such as biopsy testing of tissues identified through colonoscopy.


To leave this site and access a CME activity on colorectal cancer sponsored by, but developed independently of Quest Diagnostics